About TransEnterix (NYSEAMERICAN:TRXC)
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-137.69%
Return on Assets-83.60%
TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its quarterly earnings data on Tuesday, May, 8th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The medical instruments supplier had revenue of $4.77 million for the quarter, compared to analyst estimates of $3.81 million. TransEnterix had a negative return on equity of 137.69% and a negative net margin of 21,045.36%. View TransEnterix's Earnings History.
What price target have analysts set for TRXC?
3 brokerages have issued twelve-month price targets for TransEnterix's stock. Their predictions range from $4.00 to $4.00. On average, they expect TransEnterix's stock price to reach $4.00 in the next year. View Analyst Ratings for TransEnterix.
Are investors shorting TransEnterix?
TransEnterix saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 29,340,062 shares, an increase of 22.4% from the May 15th total of 23,962,795 shares. Based on an average trading volume of 7,418,480 shares, the days-to-cover ratio is presently 4.0 days. Currently, 18.9% of the company's shares are short sold.
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include Advanced Medical Solutions (AMS), CRH Medical (CRH), CRH Medical (CRHM), Tristel (TSTL), TSO3 (TOS), Clover (CLV), Bovie Medical (BVX), InfuSystem (INFU), Retractable Technologies (RVP), Milestone Scientific (MLSS), IsoRay (ISR), Akers Biosciences (AKR), Daxor (DXR), Omega Diagnostics Group (ODX) and Relevium Technologies (RLV).
Who are TransEnterix's key executives?
TransEnterix's management team includes the folowing people:
- Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
- Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
- Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
- Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
- Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)
Has TransEnterix been receiving favorable news coverage?
News stories about TRXC stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TransEnterix earned a news impact score of 0.05 on Accern's scale. They also gave media stories about the medical instruments supplier an impact score of 47.46 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are TransEnterix's major shareholders?
TransEnterix's stock is owned by many different of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (3.60%), Millennium Management LLC (0.94%), Royal Bank of Canada (0.58%), UBS Group AG (0.45%), Tibra Equities Europe Ltd (0.17%) and Element Capital Management LLC (0.10%). Company insiders that own TransEnterix stock include Andrea Biffi, Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, SPA Sofar, Todd Pope and Willam N Kelley. View Institutional Ownership Trends for TransEnterix.
Which institutional investors are buying TransEnterix stock?
TRXC stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, Tibra Equities Europe Ltd, Element Capital Management LLC, JPMorgan Chase & Co., Royal Bank of Canada and Barclays PLC. Company insiders that have bought TransEnterix stock in the last two years include Andrea Biffi, Richard C Pfenniger Jr, SPA Sofar and Willam N Kelley. View Insider Buying and Selling for TransEnterix.
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $4.00.
How big of a company is TransEnterix?
TransEnterix has a market capitalization of $354.65 million.
How can I contact TransEnterix?
TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for TransEnterix (TRXC)MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.